MedTrace Logo

Pertussis Acellular Vaccine Adjuvanted With TQL1055

NCT04793620 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-11-01

No results posted yet for this study

Summary

This is a phase 1 study to evaluate the safety and immunogenicity of the semisynthetic saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.

Conditions

  • Pertussis

Interventions

OTHER

TQL1055

Semisynthetic saponin adjuvant

BIOLOGICAL

Acellular pertussis vaccine

Acellular pertussis vaccine

Sponsors & Collaborators

  • Adjuvance Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Sean R Bennett, MD PhD · Adjuvance Technologies, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-06
Primary Completion
2021-08-23
Completion
2022-02-14

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04793620 on ClinicalTrials.gov